Literature DB >> 33551561

Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure.

Christie A Schumacher1, Elizabeth K Van Dril2, Kayce M Shealy3, Jennifer D Goldman4.   

Abstract

Entities:  

Year:  2021        PMID： 33551561      PMCID： PMC7839600          DOI： 10.2337/cd20-0008

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  72 in total

1.  Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability.

Authors:  Bronagh Travers; Christina O'Loughlin; Niamh F Murphy; Mary Ryder; Carmel Conlon; Mark Ledwidge; Kenneth McDonald
Journal:  J Card Fail       Date:  2007-03       Impact factor: 5.712

2.  Role of diabetes in congestive heart failure: the Framingham study.

Authors:  W B Kannel; M Hjortland; W P Castelli
Journal:  Am J Cardiol       Date:  1974-07       Impact factor: 2.778

3.  Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.

Authors:  Chintan V Dave; Sebastian Schneeweiss; Dae Kim; Michael Fralick; Angela Tong; Elisabetta Patorno
Journal:  Ann Intern Med       Date:  2019-07-30       Impact factor: 25.391

4.  Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.

Authors:  Subodh Verma; Ronald M Goldenberg; Deepak L Bhatt; Michael E Farkouh; Adrian Quan; Hwee Teoh; Kim A Connelly; Lawrence A Leiter; Jan O Friedrich
Journal:  CMAJ Open       Date:  2017-02-24

Review 5.  Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?

Authors:  Francesco Prattichizzo; Valeria De Nigris; Stefano Micheloni; Lucia La Sala; Antonio Ceriello
Journal:  Diabetes Obes Metab       Date:  2018-09-06       Impact factor: 6.577

6.  Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.

Authors:  Saumya Reddy Kankanala; Rafay Syed; Quan Gong; Boxu Ren; Xiaoquan Rao; Jixin Zhong
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

7.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

8.  Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.

Authors:  Sunder Mudaliar; Sindura Alloju; Robert R Henry
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112

Review 9.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

Review 10.  Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals.

Authors:  Toshiaki Ohkuma; Yuji Komorita; Sanne A E Peters; Mark Woodward
Journal:  Diabetologia       Date:  2019-07-18       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.